Table 5.
Clinical outcomes at prostatectomy
| Placebo | MAG-EPA | |
|---|---|---|
| N = 65 * | N = 63 * | |
| PSA mean (Std) | 6.10 (5.34) | 7.90 (8.76) |
| ISUP Grade Group, n (%) | ||
| 1 (Gleason 6) | 1 (1.5) | 3 (4.8) |
| 2 (Gleason 3 + 4) | 35 (53.9) | 27 (42.9) |
| 3 (Gleason 4 + 3) | 23 (35.4) | 23 (36.5) |
| 4 (Gleason 8) | 2 (3.1) | 5 (7.9) |
| 5 (Gleason 9) | 4 (6.2) | 5 (7.9) |
| Pathological stage, n (%) | ||
| T2 or less (N0) | 44 (67.7) | 42 (66.7) |
| T3 or T4 (N0) | 15 (23.1) | 13 (20.6) |
| N+ (any T) | 6 (9.2) | 8 (12.7) |
*The sample size is greater than for the main Ki-67 analysis as all patients who underwent radical prostatectomy are included.
p-value from †independent samples t-test, ‡ordinal logistic regression comparing the change over the intervention time between groups, adjusted for PSA, ISUP grade group (2, 3 and 4+), and clinical stage at the biopsy before surgery. PSA prostate-specific antigen, ISUP International Society of Urological Pathology, MAG-EPA monoacylglyceride-conjugated eicosapentaenoic acid.